Table 5 Results of Studies

Bleeker 2005

139/238 (58.4%)

101/170^b (59.4%)

N/A

N/A

HPV 16 6,31,33,18

81/101 (80.2%) HR vs 32/101 (31.6%) LR^a

Rosenblatt 2004

5/30 (16.7%)

7/30 (23%)

N/A

3/30 (10%)

N/A

3/7 (42.8%) HR vs 4/7 (57.2%) LR

Rombaldi 2006

62/99 (62.6%)

54/99 (54.5%)

N/A

N/A

HPV 6 11,16,40,61,84

2/54 (3.7%) HR vs 52/54 (96.3%) LR

Giraldo 2008

13/54 (24%)

14/54 (25.9%)

N/A

N/A

N/A

Only HR subtypes tested

Benevolo 2008

N/A

25/54^b (46.2%)

N/A

N/A

HPV 16 51,52,53,56,58,59

31,33,34,35,39,66,

68,73,82,6,11,40,43,44

22/25 (88%) HR vs 3/25 (12%) LR

Guzman-Esquivel 2009

N/A

4/21 (19%)

N/A

N/A

N/A

1/4 (25%) HR vs 3/4 (75%) LR

Martin-Ezquerra 2012

11/91 (12%)

8/62^b (12.9%)

22/78^b (28%)

N/A

N/A

N/A

Afonso 2013

22/60 (36.7%)

30/60 (50%)

N/A

N/A

HPV 16 45,18

18/30 (60%) HR vs 15/30 (50%) LR^a

de Lima Rocha 2012

N/A

37/43 (86%)

N/A

N/A

HPV 16 6,11,31,18,33,45

29/37 (78.3%) HR vs 23/37 (62.1%) LR^a

Rob 2017

N/A

26/36^b (72.2%)

Ν/Α

Ν/Α

HPV 16 6,11,18,30,31,33,

35,39,40,42,51,52,

53,54,56,58,59,68,

70,73,74,81,82,90

23/26 (88.4%) HR vs 8/26 (30.7%) LR^a

Vargas 2016

N/A

14/25 (56%)

N/A

N/A

HPV 83 16,62, 68,81,59,51,

31, 45,6108,34,82,

73,71,67,54,53,52

11/14 (78.5%) HR vs 10/14 (71.4%) LR^a

Lopez-Diez 2017

N/A

63/125 (50.4%)

N/A

N/A

HPV 16 18, 33,52,51,31,39

45,56,58,59,53,66,

67,68,69,70,73

N/A